Poop pills could supercharge cancer immunotherapy
NCT ID NCT04758507
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether transplanting gut bacteria from people who responded well to immunotherapy could help others with advanced kidney cancer respond better. Fifty participants received either a fecal transplant or a placebo. The goal was to see if the transplant could slow tumor growth and improve treatment outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fecal microbiota transplant (FMT) from donors responding to immunotherapy
What this could lead to
If it works, this could offer a way to boost the effectiveness of immunotherapy for advanced kidney cancer by changing the gut bacteria.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply to everyone. FMT carries risks of infection or side effects, and the benefit is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Digestive Disease Center
Rome, Rome, 00168, Italy
-
Gianluca Ianiro
Rome, Rome, 00168, Italy